安全性是可控的，与其它SG相关研究中观察到的结果一致。 2 OA04.05-SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC) ...

*Because of the small number of events (deaths and progressions) in the G1 EEC category, the confidence interval was not reliable.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

恒瑞将在 2024年 ESMO 大会上以口头报告的形式首次公布TROP-2 ADC 药物SHR-A1904治疗铂耐药卵巢癌的首次人体试验 I 期研究，目前该结果的摘要已经公布。 图片来源：ESMO 大会 SHR-A1921 是一种 ADC，由人源化抗 TROP-2 IgG1 mAb 通过基于四肽的可裂解接头连接至 DNA 拓扑异构 ...

近日，恒瑞医药自主研发的TROP-2抗体偶联药物（antibody-drug-conjugate ... 这些优惠政策都为加快新药的研发提供有利保障。 [2]National Comprehensive Cancer Network (NCCN) Guidelines: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. ...

June 13, 2024 — The reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked, has been ... Lung Cancer Study Offers ...

Lung cancer arises in tissues of the lung, usually in the cells lining air passages. The two main types are small-cell lung cancer and non-small-cell lung cancer, according to the shape of cells ...

Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program ...

Support us to deliver journalism without an agenda. A new vaccine designed to prime the immune system to recognise and fight lung cancer has been tested on UK patients for the first time.

Lung cancer starts in your lungs and can spread to other parts of your body. There are more than 20 kinds of lung cancer. Some other conditions can have similar warning signs to lung cancer.